Testing levetiracetam for those at risk of Alzheimer's
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if a medication called levetiracetam (a drug usually used for seizures) can help protect memory in people who are at higher risk for Alzheimer's but do not yet have memory problems. It involves brain scans and cognitive tests to see if the drug can reduce overactive brain activity linked to memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 55 to 85
- Normal memory and thinking skills (no dementia or mild cognitive impairment)
- At increased risk for Alzheimer's due to things like family history, memory concerns, or certain biomarkers (amyloid, tau, or APOE4)
- Have a specific type of brain activity called hippocampal hyperactivation (found on a special MRI scan)
- No history of epilepsy, recent seizures, or taking certain medications like seizure drugs or methotrexate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This Phase 2 study tests whether an added medication strategy can change brain targets linked to memory decline in people with Parkinson’s disease, including those with no memory problems or mild memory changes. It may help lower risk of developing dementia, but you must be able to safely do MRI scans and meet other health and medication rules.
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This early-stage study looks at electrical seizure-like activity in the brain in people with mild cognitive impairment or Alzheimer’s disease. It aims to understand whether this brain activity is linked to Alzheimer’s and to assess safety and responses.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
Hear when a new Hippocampal Hyperactivation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.